nach oben

Diabetologia

Erschienen in:

16.03.2016 | Mini-Review

Renaissance of leptin for obesity therapy

verfasst von: Carmelo Quarta, Miguel A. Sánchez-Garrido, Matthias H. Tschöp, Christoffer Clemmensen

Erschienen in: Diabetologia | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Diet-induced obesity and its metabolic comorbidities constitute an overwhelming health crisis and there is an urgent need for safe and effective pharmacological interventions. Being largely shelved for decades, scientists are now revisiting the anti-obesity virtues of leptin. Whereas it remains evident that leptin as a stand-alone therapy is not an effective approach, the potential for employing sensitising pharmacology to unleash the weight-lowering properties of leptin has injected new hope into the field. Fascinatingly, these leptin-sensitising agents seem to act via distinct metabolic pathways and may thus, in parallel with their clinical development, serve as important research tools to progress our understanding of the molecular, physiological and behavioural pathways underlying energy homeostasis and obesity pathophysiology. This review summarises a presentation given at the ‘Is leptin coming back?’ symposium at the 2015 annual meeting of the EASD. It is accompanied by two other reviews on topics from this symposium (by Thomas Meek and Gregory Morton, DOI: 10.1007/s00125-016-3898-3, and by Gerald Shulman and colleagues, DOI: 10.1007/s00125-016-3909-4) and an overview by the Session Chair, Ulf Smith (DOI: 10.1007/s00125-016-3894-7).

van der Klaauw AA, Farooqi IS (2015) The hunger genes: pathways to obesity. Cell 161:119–132CrossRefPubMed

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372:425–432CrossRefPubMed

Heymsfield SB, Greenberg AS, Fujioka K et al (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568–1575CrossRefPubMed

Myers MG Jr, Leibel RL, Seeley RJ, Schwartz MW (2010) Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab 21:643–651CrossRefPubMedPubMedCentral

Oral EA, Simha V, Ruiz E et al (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570–578CrossRefPubMed

Farooqi IS, Jebb SA, Langmack G et al (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341:879–884CrossRefPubMed

Farooqi IS, Matarese G, Lord GM et al (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110:1093–1103CrossRefPubMedPubMedCentral

Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U (2015) Treatment of obesity with celastrol. Cell 161:999–1011CrossRefPubMed

de Git KC, Adan RA (2015) Leptin resistance in diet-induced obesity: the role of hypothalamic inflammation. Obes Rev 16:207–224CrossRefPubMed

10.

Pedroso JA, Buonfiglio DC, Cardinali LI et al (2014) Inactivation of SOCS3 in leptin receptor-expressing cells protects mice from diet-induced insulin resistance but does not prevent obesity. Mol Metab 3:608–618CrossRefPubMedPubMedCentral

11.

Picardi PK, Caricilli AM, de Abreu LL, Carvalheira JB, Velloso LA, Saad MJ (2010) Modulation of hypothalamic PTP1B in the TNF-α-induced insulin and leptin resistance. FEBS Lett 584:3179–3184CrossRefPubMed

12.

Lantz KA, Hart SG, Planey SL et al (2010) Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice. Obesity 18:1516–1523CrossRefPubMed

13.

Byun K, Gil SY, Namkoong C et al (2014) Clusterin/ApoJ enhances central leptin signaling through Lrp2-mediated endocytosis. EMBO Rep 15:801–808CrossRefPubMedPubMedCentral

14.

Roth JD, Roland BL, Cole RL et al (2008) Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci U S A 105:7257–7262CrossRefPubMedPubMedCentral

15.

Müller TD, Sullivan LM, Habegger K et al (2012) Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 18:383–393CrossRefPubMed

16.

Kim YW, Kim JY, Park YH et al (2006) Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 55:716–724CrossRefPubMed

17.

Yan C, Yang Y, Saito K et al (2015) Meta-chlorophenylpiperazine enhances leptin sensitivity in diet-induced obese mice. Br J Pharmacol 172:3510–3521CrossRefPubMed

18.

Wang L, Barachina MD, Martinez V, Wei JY, Tache Y (2000) Synergistic interaction between CCK and leptin to regulate food intake. Regul Pept 92:79–85CrossRefPubMed

19.

Unniappan S, Kieffer TJ (2008) Leptin extends the anorectic effects of chronic PYY(3-36) administration in ad libitum-fed rats. Am J Physiol Regul Integr Comp Physiol 295:R51–R58CrossRefPubMedPubMedCentral

20.

Ravussin Y, Leibel RL, Ferrante AW Jr (2014) A missing link in body weight homeostasis: the catabolic signal of the overfed state. Cell Metab 20:565–572CrossRefPubMedPubMedCentral

21.

Ottaway N, Mahbod P, Rivero B et al (2015) Diet-induced obese mice retain endogenous leptin action. Cell Metab 21:877–882CrossRefPubMed

22.

Ozcan L, Ergin AS, Lu A et al (2009) Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 9:35–51CrossRefPubMed

23.

Cakir I, Cyr NE, Perello M et al (2013) Obesity induces hypothalamic endoplasmic reticulum stress and impairs proopiomelanocortin (POMC) post-translational processing. J Biol Chem 288:17675–17688CrossRefPubMedPubMedCentral

24.

Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D (2008) Hypothalamic IKKβ/NF-κB and ER stress link overnutrition to energy imbalance and obesity. Cell 135:61–73CrossRefPubMedPubMedCentral

25.

Hosoi T, Baba S, Ozawa K (2014) Therapeutic potential of flurbiprofen against obesity in mice. Biochem Biophys Res Commun 449:132–134CrossRefPubMed

26.

Hosoi T, Yamaguchi R, Noji K et al (2014) Flurbiprofen ameliorated obesity by attenuating leptin resistance induced by endoplasmic reticulum stress. EMBO Mol Med 6:335–346PubMedPubMedCentral

27.

Henstridge DC, Whitham M, Febbraio MA (2014) Chaperoning to the metabolic party: the emerging therapeutic role of heat-shock proteins in obesity and type 2 diabetes. Mol Metab 3:781–793CrossRefPubMedPubMedCentral

28.

Kars M, Yang L, Gregor MF et al (2010) Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 59:1899–1905CrossRefPubMedPubMedCentral

29.

Park SW, Ozcan U (2013) Potential for therapeutic manipulation of the UPR in disease. Semin Immunopathol 35:351–373CrossRefPubMedPubMedCentral

30.

Ma X, Xu L, Alberobello AT et al (2015) Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis. Cell Metab 22:695–708CrossRefPubMed

31.

Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415–445CrossRefPubMed

32.

Valdearcos M, Xu AW, Koliwad SK (2015) Hypothalamic inflammation in the control of metabolic function. Annu Rev Physiol 77:131–160CrossRefPubMed

33.

Thaler JP, Yi CX, Schur EA et al (2012) Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 122:153–162CrossRefPubMedPubMedCentral

34.

Kleinridders A, Schenten D, Konner AC et al (2009) MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab 10:249–259CrossRefPubMedPubMedCentral

35.

Milanski M, Degasperi G, Coope A et al (2009) Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J Neurosci 29:359–370CrossRefPubMed

36.

Gao Y, Ottaway N, Schriever SC et al (2014) Hormones and diet, but not body weight, control hypothalamic microglial activity. Glia 62:17–25CrossRefPubMedPubMedCentral

37.

De Souza CT, Araujo EP, Bordin S et al (2005) Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology 146:4192–4199CrossRefPubMed

38.

Zabolotny JM, Kim YB, Welsh LA, Kershaw EE, Neel BG, Kahn BB (2008) Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem 283:14230–14241CrossRefPubMedPubMedCentral

39.

Thaler JP, Guyenet SJ, Dorfman MD, Wisse BE, Schwartz MW (2013) Hypothalamic inflammation: marker or mechanism of obesity pathogenesis? Diabetes 62:2629–2634CrossRefPubMedPubMedCentral

40.

Kim JG, Suyama S, Koch M et al (2014) Leptin signaling in astrocytes regulates hypothalamic neuronal circuits and feeding. Nat Neurosci 17:908–910CrossRefPubMed

41.

Yu Y, Wu Y, Szabo A et al (2013) Teasaponin reduces inflammation and central leptin resistance in diet-induced obese male mice. Endocrinology 154:3130–3140CrossRefPubMed

42.

Posey KA, Clegg DJ, Printz RL et al (2009) Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 296:E1003–E1012CrossRefPubMedPubMedCentral

43.

Jang PG, Namkoong C, Kang GM et al (2010) NF-κB activation in hypothalamic pro-opiomelanocortin neurons is essential in illness- and leptin-induced anorexia. J Biol Chem 285:9706–9715CrossRefPubMedPubMedCentral

44.

Oh IS, Thaler JP, Ogimoto K, Wisse BE, Morton GJ, Schwartz MW (2010) Central administration of interleukin-4 exacerbates hypothalamic inflammation and weight gain during high-fat feeding. Am J Physiol Endocrinol Metab 299:E47–E53CrossRef

45.

Benzler J, Ganjam GK, Pretz D et al (2015) Central inhibition of IKKβ/NF-κB signaling attenuates high-fat diet-induced obesity and glucose intolerance. Diabetes 64:2015–2027CrossRefPubMed

46.

Kay JP, Alemzadeh R, Langley G, D’Angelo L, Smith P, Holshouser S (2001) Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metab Clin Exp 50:1457–1461CrossRefPubMed

47.

Glueck CJ, Fontaine RN, Wang P et al (2001) Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metab Clin Exp 50:856–861CrossRefPubMed

48.

Fruehwald-Schultes B, Oltmanns KM, Toschek B et al (2002) Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metab Clin Exp 51:531–536CrossRefPubMed

49.

Aubert G, Mansuy V, Voirol MJ, Pellerin L, Pralong FP (2011) The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metab Clin Exp 60:327–334CrossRefPubMed

50.

Mueller WM, Stanhope KL, Gregoire F, Evans JL, Havel PJ (2000) Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes Res 8:530–539CrossRefPubMed

51.

Aronne L, Fujioka K, Aroda V et al (2007) Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 92:2977–2983CrossRefPubMed

52.

Ravussin E, Smith SR, Mitchell JA et al (2009) Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17:1736–1743CrossRefPubMedPubMedCentral

53.

Mietlicki-Baase EG, Olivos DR, Jeffrey BA, Hayes MR (2015) Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake. Am J Physiol Endocrinol Metab 308:E1116–E1122CrossRefPubMed

54.

Turek VF, Trevaskis JL, Levin BE et al (2010) Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 151:143–152CrossRefPubMed

55.

Sinha G (2014) Leptin therapy gains FDA approval. Nat Biotechnol 32:300–302CrossRefPubMed

56.

Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P (2016) Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol 9:59–68CrossRefPubMed

57.

Rodriguez AJ, Mastronardi CA, Paz-Filho GJ (2015) New advances in the treatment of generalized lipodystrophy: role of metreleptin. Ther Clin Risk Manag 11:1391–1400PubMedPubMedCentral

58.

Finan B, Clemmensen C, Muller TD (2015) Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists. Mol Cell Endocrinol 418P1:42–54CrossRef

59.

Day JW, Ottaway N, Patterson JT et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749–757CrossRefPubMed

60.

Clemmensen C, Chabenne J, Finan B et al (2014) GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes 63:1422–1427CrossRefPubMed

61.

Cegla J, Troke RC, Jones B et al (2014) Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63:3711–3720CrossRefPubMed

62.

Tan TM, Field BC, McCullough KA et al (2013) Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62:1131–1138CrossRefPubMedPubMedCentral

63.

Finan B, Yang B, Ottaway N et al (2012) Targeted estrogen delivery reverses the metabolic syndrome. Nat Med 18:1847–1856CrossRefPubMedPubMedCentral

64.

Simonds SE, Cowley MA (2013) Hypertension in obesity: is leptin the culprit? Trends Neurosci 36:121–132CrossRefPubMed

65.

Chan JL, Koda J, Heilig JS et al (2015) Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. Clin Endocrinol. doi:10.1111/cen.12980

Titel: Renaissance of leptin for obesity therapy
verfasst von: Carmelo Quarta
Miguel A. Sánchez-Garrido
Matthias H. Tschöp
Christoffer Clemmensen
Publikationsdatum: 16.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Diabetologia / Ausgabe 5/2016
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-016-3906-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Methylation of insulin DNA in response to proinflammatory cytokines during the progression of autoimmune diabetes in NOD mice

Microbial transmission from mothers with obesity or diabetes to infants: an innovative opportunity to interrupt a vicious cycle

Is leptin coming back? A short introduction to the presentations in this symposium session at the 2015 annual meeting of the EASD

Adipose tissue macrophages: going off track during obesity

Exosome-like vesicles released from lipid-induced insulin-resistant muscles modulate gene expression and proliferation of beta recipient cells in mice